文献速递药物不良反应与药物警戒

法国Mirena左炔诺孕酮宫内节育器不良事件报告及媒体报道影响

Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-31

该研究提取法国国家药物警戒数据库中1995年7月21日至2017年8月4日所有涉及Mirena的报告,以2017年5月15日媒体报道峰值为界分段比较。共纳入3224份报告,峰值前510份(15.8%)、峰值后2714份(84.2%);峰值后报告者以患者为主(98.6%),报告的不良事件类型亦明显改变,提示媒体报道影响自发报告的模式与内容。

要点

  • 媒体报道峰值后报告量占84.2%,报告主体由医务人员转为患者(98.6%)
  • 峰值后每份报告不良事件数中位数为6(范围1-37),峰值前为1(范围1-17)
  • 峰值后焦虑抑郁障碍(38.8% vs 10.6%)与性功能障碍(47.3% vs 6.9%)报告增多

核心结论

  • 媒体报道显著影响Mirena自发报告的数量、报告者类型及不良事件类型,并由此产生焦虑抑郁障碍与性功能障碍方面的信号。

研究设计与样本

  • 基于法国国家药物警戒数据库的回顾性描述性研究,提取1995年7月21日至2017年8月4日所有涉及Mirena的病例报告,以2017年5月15日媒体报道峰值为界分段比较。

主要发现

  • 共纳入3224份报告,峰值前510份(15.8%)、峰值后2714份(84.2%)。
  • 峰值前76.5%的报告来自医务人员,报告时间中位数5.5个月(四分位距1.7-18.6),每份报告不良事件数中位数1(范围1-17)。
  • 峰值后98.6%的报告来自患者,报告时间中位数21个月(四分位距8.1-45.5),每份报告不良事件数中位数6(范围1-37)。
  • 峰值后焦虑抑郁障碍报告占38.8%(峰值前10.6%),性功能障碍占47.3%(峰值前6.9%)。
  • 峰值后体重增加报告占42.3%(峰值前10.2%),胃肠道疼痛占19.1%(峰值前3.5%),肌肉骨骼疼痛占22.2%(峰值前4.5%)。

临床怎么用

  • 临床药学评估Mirena相关不良事件报告时,应结合媒体报道背景判断报告偏倚,避免仅凭自发报告数量变化推断风险。
  • 对患者主动报告的焦虑抑郁、性功能障碍等症状,仍需结合用药时间与因果评估流程审慎判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In 2017, concerns regarding adverse events (AEs) associated with the Mirena levonorgestrel intrauterine device were largely echoed in the media in France. This resulted in a tremendous reporting of AEs to pharmacovigilance centres. The aim of this study was to describe the reporting of AEs regarding Mirena in France and to study the impact of media coverage on this reporting. METHODS: All cases reports involving Mirena recorded in the French national pharmacovigilance database from marketing (21 July 1995) until 04 August 2017 were extracted. To allow studying the influence of mediatisation, reports were described separately for the periods preceding and following the observed media coverage peak (15 May 2017). RESULTS: Overall, 3224 reports were considered, 510 (15.8%) recorded before the media coverage peak, and 2714 (84.2%) after. Before the peak, 76.5% of reports originated from health professionals; median time-to-report was of 5.5 months (interquartile range: 1.7-18.6), and median number of AEs per report was 1 (range: 1-17). After the peak, 98.6% originated from patients; median time-to-report was 21 months (interquartile range: 8.1-45.5), and median number of AEs per report was 6 (range: 1-37). After the peak, most reports mentioned anxio-depressive disorders (38.8 vs 10.6% before) or sexual disorders (47.3 vs 6.9%). Other emphasised AEs were weight increase (42.3 vs 10.2%) and pain (gastrointestinal, 19.1 vs 3.5%; musculoskeletal, 22.2 vs 4.5%). CONCLUSION: This study highlighted the importance of mediatisation impact on spontaneous reporting with changes concerning amounts of reports, type of reporter, and type of reported AEs. For Mirena, this led to generate signals regarding anxio-depressive and sexual disorders.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Langlade C, Gouverneur A, Bosco-Lévy P, et al. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage. Br J Clin Pharmacol. 2019. PMID: 31218710. doi:10.1111/bcp.14027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。